Marathon Sells Muscular-Dystrophy Drug to PTC After Pricing Scrutiny
Marathon Pharmaceuticals has struck a deal to sell its muscular dystrophy treatment to PTC Therapeutics, one month after Marathon’s $89,000 price-tag for the drug spurred an outcry from patient advocates and federal lawmakers.